A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
Status:
Completed
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in
participants with locally advanced or metastatic non-small cell lung cancer. Participants
received daily oral doses of 150 mg Tarceva. The anticipated time on study treatment was 12
months.